Improving Practicality of Cell and Gene Therapies

Video

Josh Ludwig, global director, commercial operations, ScaleReady, discussed making cell and gene therapy widely practical and viable for patients with cancer.

This content originally appeared on our sister site, Cancer Network.

CancerNetwork® spoke with Josh Ludwig, global director, commercial operations, ScaleReady, to learn more about the joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf that launched in January 2021. The collaboration aims to make cell and gene therapy practical and viable for patients with cancer.

During the Deep Dive epsiode from the Medical World News® broadcast, Ludwig discussed how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also detailed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Related Content
Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024

Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024

Noah Stansfield
July 24th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Haydar Frangoul, MD, Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial

Biotechs Seek Federal Coverage of Fertility Preservation Before Gene Therapy

Victoria Johnson
July 24th 2024
Article

Both companies have received unfavorable opinions from the Office of the Inspector General on the matter.

Silviu Itescu, MBBS, FRACP, chief Executive Officer and Managing Director, Mesoblast

FDA Accepts Mesoblast’s BLA for Remestemcel-L for Steroid-Refractory GvHD

Victoria Johnson
July 23rd 2024
Article

After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.

Ash Alizadeh, MD, PhD, professor of medicine and member, Stanford Cancer Institute

Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T

Victoria Johnson
July 22nd 2024
Article

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – July 19, 2024

CGTLive Staff
July 19th 2024
Article

Review top news and interview highlights from the week ending July 19, 2024.

Sarcoma Awareness Month 2024: Looking Back at a Year of Progress for Cell and Gene Therapy

Sarcoma Awareness Month 2024: Looking Back at a Year of Progress for Cell and Gene Therapy

Noah Stansfield
July 19th 2024
Article

In observance of Sarcoma Awareness Month, held annually in July, we took a look back at the past year's news in cell/gene therapy for this cancer.

© 2024 MJH Life Sciences

All rights reserved.